1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Biosergen AB

Biosergen AB

0.49
SEK
+0.00
(-0.40%)
11.32MMarket Cap
Nov 18Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1.67
-7.9
-7.06
-3.45
-0.89
-1.77
- -
Free Cash Flow per Basic Share
-1.14
-8.69
-6.1
-4.17
-0.47
-1.72
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.72
4.14
3.48
0.27
2.25
0.55
0.03
Tangible Book Value per Share
-2.72
4.14
3.48
0.27
2.25
0.55
0.03
Basic Weighted Avg Shares
4
4
5
8
21
21
21
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-7
-34
-34
-27
-19
-38
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
Working Capital
-11
20
23
2
48
12
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
-11
20
23
2
48
12
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-158.26
-217.08
-76.29
-126.77
- -

Capital Structure

SEK

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
122
93
11

Working Capital

SEK

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
Total Current Assets
26
20
10
Cash, Cash Equivalents & STI
23
15
3
Accounts Receivable, Net
3
6
7
Inventories
- -
- -
- -
Total Current Liabilities
5
8
10
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
347.88%
-75.6%
Free Cash Flow
- -
181.02%
261.67%
Net Income, GAAP
- -
91.61%
98.04%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.88
-0.44
-0.33
-0.1
-0.89
2025
-0.24
-0.51
-0.57
-0.58
-1.77
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tine Kold Olesen
Full Time Employees
1
Sector
Health technology
Industry
Biotechnology
Address
Fogdevreten 2 Solna Sweden 171 65
IPO Date
Jun 24, 2021
Website
biosergen.net
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Biosergen AB (publ) (BIOSGN.ST) is a Sweden-based biotechnology company that develops innovative antifungal drugs targeting invasive fungal infections in immunocompromised patients, including those with AIDS, cancer, and transplant recipients; its lead product candidate, BSG005, is a genetically improved polyene macrolide demonstrating superior safety and potency compared to existing treatments, with fungicidal activity against a broad spectrum of fungi such as Candida and Aspergillus species. Founded in 2021 and headquartered in Solna, Sweden, the company conducts research and development through laboratory facilities originally in Trondheim, Norway, and global sites, while operating primarily in Europe with commercial rights retained globally except in India. Recent developments include a strategic partnership with Alkem Laboratories Limited for a proof-of-concept study in India, where the first patient dosed with BSG005 recovered from fungal disease; a SEK 26.4 million rights issue in 2024 funding the first-in-patient trial as rescue therapy; exercise of TO3 warrants raising SEK 44.9 million in December 2024; Phase 1 completion confirming safety in 38 healthy volunteers with dose escalation approvals; appointment of Tine Kold Olesen as CEO in February 2024; and addition of Marco Taglietti to the board in 2025, alongside FDA orphan drug designation for BSG005 providing U.S. market exclusivity post-approval and patent protection until 2043.